ALQ ALS Ltd
- 13.190
- +0.090+0.69%
ALS Ltd News
State Street Corporation Acquires 5.1% Stake in ALS Ltd
State Street Corporation Exits ALS Ltd Stake
State Street Corporation Acquires Stake in ALS Ltd
Investing in ALS (ASX:ALQ) Five Years Ago Would Have Delivered You a 87% Gain
ALS Ltd. (CPBLF) Was Downgraded to a Hold Rating at Morgans
Morgans Financial Downgrades ALS to Hold From Add, Price Target at AU$13.70
ALS (ASX:ALQ) has an average rating of outperform and price targets ranging from AU$8.90 to AU$13.90, according to analysts polled by CapitalIQ. Price (AUD): $13.13, Change: $+0.08, Percent Change: +0
ALS Target Price Raised 2.6% to A$13.70/Share by Morgans>ALQ.AU
ALS Target Price Raised 2.6% to A$13.70/Share by Morgans>ALQ.AU
Analysts Offer Insights on Industrial Goods Companies: Evolv Technologies Holdings (EVLV), ALS Ltd. (OtherCPBLF) and Chart Industries (GTLS)
ALS Ltd. (CPBLF) Gets a Buy From Jarden
ALS Target Price Raised 2.3% to A$13.30/Share by UBS>ALQ.AU
ALS Target Price Raised 2.3% to A$13.30/Share by UBS>ALQ.AU
Jarden Adjusts ALS's Price Target to AU$13.70 From AU$13.80, Keeps at Buy
ALS (ASX:ALQ) has an average rating of outperform and price targets ranging from AU$8.60 to AU$14.25, according to analysts polled by CapitalIQ. Price (AUD): $13.07, Change: $-0.66, Percent Change: -4
ALS Price Target Cut 2.5% to A$13.90/Share by Macquarie
ALS Price Target Cut 2.5% to A$13.90/Share by Macquarie
Buy Rating Affirmed for ALS Ltd. Following Strategic Nuvisan Acquisition and Positive Financial Outlook
AU Evening Wrap: Australian Shares Rise 0.5% Amid Real Estate Gains
Ten of eleven sectors finished higher, as the benchmark index rebounded from Friday's 0.15% slip.
Leading Brokers Name 3 ASX Shares to Buy Today 25 March 2024
With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
ALS to Acquire Nuvisan; Shares Down 5%
Analytical and testing services company ALS (ASX:ALQ) has agreed with Nuvisan Pharma Holding GmbH to acquire the remaining 51% interest in Nuvisan, which includes Nuvisan GmbH and Innovation Campus Be
ALS Expects EUR20 Million of Restructuring Costs Over Two Years
ALS Expects EUR20 Million of Restructuring Costs Over Two Years
ALS Expects to Write Down Existing 49% Stake in FY 2024 Report
ALS Expects to Write Down Existing 49% Stake in FY 2024 Report
ALS: Nuvisan Generated A$245 Million in 2023 Revenue
ALS: Nuvisan Generated A$245 Million in 2023 Revenue
ALS Taking Full Ownership Following Strategic Review of Nuvisan
ALS Taking Full Ownership Following Strategic Review of Nuvisan
Analysis
Price Target
No Data
